Overview

IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

Status:
Active, not recruiting

Trial end date:
2025-12-31

Target enrollment:

Participant gender:

Summary

This research study is studying a drug as a possible treatment for IDH1-mutant myeloid neoplasms. -The drug involved in this study is ivosidenib (AG-120)

Phase:

Phase 1

Details

Lead Sponsor:

Massachusetts General Hospital

Collaborator:

Agios Pharmaceuticals, Inc.

Treatments:

Ivosidenib